Previous studies [26,28] have described that positive PD-L1 expression is correlated with worse prognosis in numerous human cancers and also suggested that such expression could serve as a biomarker which predicts the response to anti-PD-1/PD-L1 therapies. Here, PDCD1 is linked to cancer.